A Placebo-Controlled Multi-Center Phase 2 Study of Ublituximab, a Third-Generation Anti-CD20 Monoclonal Antibody, in Patients With Relapsing Forms of Multiple Sclerosis.

Trial Profile

A Placebo-Controlled Multi-Center Phase 2 Study of Ublituximab, a Third-Generation Anti-CD20 Monoclonal Antibody, in Patients With Relapsing Forms of Multiple Sclerosis.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 02 Feb 2018

At a glance

  • Drugs Ublituximab (Primary)
  • Indications Multiple sclerosis
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors TG Therapeutics Inc
  • Most Recent Events

    • 02 Feb 2018 According to a TG Therapeutics media release, Results(n=40) were presented at the Third Annual ACTRIMS Forum 2018.
    • 24 Jan 2018 According to a TG Therapeutics media release, data from this trial will be presented at the upcoming third annual Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2018.
    • 31 Oct 2017 According to a TG Therapeutics Inc media release, a conference call will be held on Thursday, November 2, 2017 at 8:30am ET to review the data from the trial presented at the 7th Joint ECTRIMS-ACTRIMS meeting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top